A world leader
  in patient-centered care

 

Training the next generation
  of cancer researchers

 

The most advanced
  treatment options available

 

Dana-Farber/Boston Children's remains nation's #1 pediatric cancer program

June 21, 2016

For the third year in a row, U.S. News & World Report named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the nation's #1 pediatric cancer program in its new 2016-17 Best Children's Hospitals rankings.

Discover Care Believe - boy on pier

"Discover. Care. Believe." highlights Dana-Farber breakthroughs

Dana-Farber Cancer Institute has launched DiscoverCareBelieve.org, a new platform to illustrate what sets Dana-Farber apart — in research discovery... in expert, compassionate care... and in our strong belief in progress for people with cancer everywhere.

Website
Video
What do you #DiscoverCareBelieve?

Charles Fuchs, MD, MPH

New Online Resource for Precision Cancer Medicine

Clinicians at Dana-Farber/Brigham and Women's Cancer Center are now armed with specialized tests to create a precise "tumor profile" for each patient's cancer. Learn about the latest thinking in precision cancer medicine from our researchers and clinicians, and explore a searchable database of clinical trials that focus on targeted therapies by disease, gene, and mutation.

Researchers identify calorie-burning pathway in fat cells with potential for obesity treatment
June 30, 2016

Investigators at Dana-Farber have identified a natural molecular pathway that enables cells to burn off calories as heat rather than store them as fat.

Surgery can lengthen survival of metastatic kidney cancer patients treated with targeted therapies, study finds
June 20, 2016

Researchers find cytoreductive nephrectomy may offer an overall survival benefit to patients with metastatic kidney cancer who are treated with targeted therapies.

Dana-Farber joins forces with Boston medical institutions to establish first area cell transplantation center
June 16, 2016

The Harvard Stem Cell Institute (HSCI), three of Harvard’s clinical affiliates, including Dana-Farber Cancer Institute (DFCI), and a biopharmaceutical company have formed a unique collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure for diabetes.

Dana-Farber researcher selected as 2016 Pew-Stewart Scholar
June 10, 2016

Dana-Farber researcher Stephanie Dougan, PhD, was one of five early-career cancer scientists selected as a 2016 Pew-Stewart Scholar.

Putting Breast Cancer on a Diet (New York Times)

June 28, 2016

Dr. Jennifer Ligibel is leading a study to see if weight loss should be prescribed as a treatment for breast cancer.

Reality check from Eric Lander: Majority of cancer cures will take decades (Boston Globe)
June 27, 2016

Dana-Farber is leading a national effort with The Broad to encourage patients with metastatic breast cancer to share their medical information.

Boston Children’s Hospital is best pediatric hospital in the country, report says (Boston.com)
June 21, 2016

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center was ranked highest for treating pediatric cancer in the latest rankings compiled by U.S. News & World Report.

 

Easing a patient’s pain — even without proof it works (Boston Globe)
June 20, 2016

Dr. Jennifer Ligibel comments on Dana-Farber offering complementary therapies to help patients.

Lung Cancer Trial Stopped After Jimmy Carter Drug Shrinks Tumor (NBC News)
June 17, 2016

Dr. Pasi Janne comments on the immunotherapy drug Keytruda for treating patients with non-small cell lung cancer.

Stem cell factory opens door for trials of personalized diabetes treatment (Boston Globe)
June 16, 2016

In a step that could lead to a new diabetes treatment, Dana-Farber has joined several Boston-area hospitals and medical institutions to make personalized cell-based therapies and organize clinical trials.

 

Two Immunotherapy Combinations Show Promise in Glioblastoma (Targeted Oncology)
June 14, 2016

Dr. David Reardon discusses the efficacy of two immunotherapy combinations for Glioblastoma.

discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpuf
David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Physician, Dana-Farber Cancer Institute, discusses the safety profiles and efficacy of the two immunotherapy combinations, as well as future research into immune correlative biomarker assays, which may become increasingly important, he says. - See more at: http://www.targetedonc.com/news/two-immunotherapy-combinations-show-promise-in-glioblastoma#sthash.KJvmA8fU.dpufDr. D

New studies rely on the Internet for help treating cancer patients (Fox News)
June 07, 2016

Dr. Nikhil Wagle led a study showing how the Internet can help recruit patients for breast cancer research.

 

Lunch & Learn Integrative Therapies Educational Series: Exercising with Neuropathy

June 30, 2016

12:00 PM - 1:00 PM

Eleanor and Maxwell Blum Patient and Family Resource Center, Yawkey 1

Led by Patricia Arcari and Heather Woods from the Zakim Center for Integrative Therapies, and Nancy Campbell, Dana-Farber's exercise physiologist.

Learn a variety of strategies to manage stress and develop resilience through movement, nutrition, expressive arts, and meditation.

Participants are invited to bring their own lunch.

Participants are welcome in person or on the phone at (866) 763-0680, and use passcode 8530531. To register, please call (617) 632-5570.

more

Mind Body Resilience

June 30, 2016

1:30 PM - 3:00 PM

Smith Building, Room 330

Patient sessions start Wednesday, June 15 | 1:30 - 3:00 PM

Staff sessions start Thursday, June 16 | 4:00 - 5:30 PM

 

This is an eight-week program led by Patty Arcari, PhD, RN, program manager of meditation and mindfulness programs in the Zakim Center, for Dana-Farber patients and staff to learn how to manage stress and nurture resilience.

Attendance at all sessions is required.

There is an optional ninth week session on positive psychology, which involves meeting with a strength-based coach.

For more information and to register, please contact the Zakim Center at 617-632-3322 or email Zakim_Center@dfci.harvard.edu.

more

Qigong(1)

July 01, 2016

10:00 AM - 11:30 AM

Smith Building, Room 330

In this class you will learn exercises of the mind/body through mindfulness awareness and fluid movement. These techniques will help you to relax, increase concentration, while utilizing the mind, body and spirit to help improve quality of life. This class is open to patients who have been newly diagnosed with cancer, are receiving treatment, or in remission. Family, friends and staff are welcome. Please call the Zakim Center to register at 617-632-3322 or email Zakim_Center@dfci.harvard.edu.

more

  •  
  • Patient referral information, clinical resources and more.

  • Make an Appointment


    For adults:
    877-442-3324

    Quick access: Appointments as soon as the next day for new adult patients

    For children:
    888-733-4662


    Make Appointment Online

  • Clinical Trials

    Search current cancer clinical trials at Dana-Farber.

  • How to Help

    Yawkey Center for Cancer Care entrance

    There are many ways to support Dana-Farber and the Jimmy Fund.

    give now button
  • Top-ranked

    • U.S. News Best Hospitals Cancer 2015-2016 logo    U.S. News Best Children's Hospitals Cancer 2015-2016 logo

    Top-ranked cancer center in New England for adults (with Brigham and Women's Hospital) — #1 in the nation for children (with Boston Children's Hospital)

  • Dana-Farber Blog

    Insight Blog screenshot

    Insight features the latest in cancer care and research news from Dana-Farber.
    Read the blog

  • Dana-Farber eNewsletter

    Dana-Farber Spotlight

    Stay current on the latest news by signing up for Spotlight, our email newsletter.
    View current issue
    Subscribe now

6/30/2016 3:23:44 PM